BACKGROUND: Current treatments for obsessive-compulsive disorder (OCD), including serotonin reuptake inhibitors and cognitive-behavioral therapy, are often insufficient. Psilocybin, a 5HT2a agonist psychedelic, has shown promise for treating OCD, but rigorous evidence is still needed. AIMS: This randomized clinical trial evaluated safety, tolerability, and benefit of multiple psilocybin doses...
Psychedelic-assisted therapy shows promise for treating various mental health conditions; however, its reliance on intensive psychological preparation limits its broader application. Digital health interventions have the potential to address this limitation by providing structured, accessible and scalable preparation solutions. This randomised controlled feasibility trial aims to evaluate the...
Background: Cancer patients often experience significant emotional burdens due to the diagnosis, treatment process, and uncertainty regarding their prognosis. Psilocybin, a psychedelic compound found in certain mushroom species, has gained increasing attention in mental health research for its potential therapeutic effects in treating depression and anxiety. Methods: This systematic review...
Introdução: Os transtornos psiquiátricos representam um importante desafio na saúde pública mundial, com impacto significativo na qualidade de vida, funcionalidade e mortalidade dos pacientes. Embora os psicofármacos tradicionais, como antidepressivos, antipsicóticos e estabilizadores de humor sejam amplamente utilizados, muitos indivíduos apresentam resposta insatisfatória, falha terapêutica...
Psychedelic compounds such as psilocybin, Lysergic Acid Diethylamide (LSD), N,Ndimethyltryptamine (DMT), and 3,4-methylenedioxymethamphetamine (MDMA) are emerging as novel therapeutics for neuropsychiatric disorders, including depression, Post-Traumatic Stress Disorder (PTSD), and addiction. Acting primarily through serotonin 5-HT2A receptor agonism, they activate intracellular cascades...
This article investigates the novel therapeutic approach of “amplified psychoanalysis” through a detailed examination of the Ygg case, which offers a descriptive single-case illustration of the integration of MDMA-assisted therapy with traditional psychoanalytic treatment for obsessive-compulsive disorder (OCD). The study explores how subjective experience induced by MDMA can interact with an...
The literature on psychedelic experiences often highlights their transformative potential. This raises ethical questions about informed consent in psychedelic-assisted therapy: if the altered state of consciousness induced by psychedelic drugs can profoundly alter a person's value system in ways that are epistemically inaccessible to them beforehand, it is unclear whether their informed consent...
Recent clinical trials conducted by both industry and academic institutions have demonstrated the therapeutic potential of psychedelics for a variety of mental health conditions in adults. Considering the neurodevelopmental aspects of many of these disorders and the widespread occurrence of these conditions among younger individuals, there is increasing interest in exploring the potential for...
Abstract New treatments for depression are needed that combine robust efficacy with improved scalability. Although psilocybin has demonstrated antidepressant effects in Phase 3 clinical trials, some of its psychedelic effects limit tolerability, necessitating administration in highly supervised clinical settings, and thus motivating development of serotonergic therapeutics that preserve...
This paper aims to identify the effects of ayahuasca on humans and more specifically how this substance defines changes within psychological and behavioral patterns, including experience of emotions, decision-making processes, and life changes. The demand for the new-wave of antidepressants based on psychedelic substances places emphasis on the study of how the powerful ayahuasca, a...